Search research articles
Contact Us
Filters
Showing results (41-50 of 84) with videos related to
Page
of 9
Sort By:
Clinical Pharmacokinetics
|
May 7, 2021
Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
Shirley M Tsunoda, Christopher Gonzales, Alan K Jarmusch, et al.
Journal of Analytical Toxicology
|
May 1, 2014
Variability in metabolism of imipramine and desipramine using urinary excretion data
Kelley Ramey, Joseph D Ma, Brookie M Best, et al.
Journal of Pain & Palliative Care Pharmacotherapy
|
January 15, 2014
A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients
Joseph D Ma, John M Horton, Michael Hwang, et al.
Journal of Pain & Palliative Care Pharmacotherapy
|
September 12, 2018
Opioid and Benzodiazepine Relative Use in Breast Cancer Patients Before, During, and After Curative Chemotherapy
Warren H Yau, Eric J Roeland, Carolyn Revta, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2006
Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults
Joseph D Ma, Anne N Nafziger, Stephen A Villano, et al.
Journal of Palliative Medicine
|
January 22, 2015
Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants
Andrew R Bruggeman, Sean F Heavey, Joseph D Ma, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
May 1, 2012
Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation
Anh N Nguyen, Justin T Hoffman, Shirley M Tsunoda, et al.
Journal of Opioid Management
|
June 20, 2014
Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine
Jennifer M Cao, Joseph D Ma, Candis M Morello, et al.
Journal of Health Care Chaplaincy
|
December 6, 2021
Spiritual AIM: assessment and documentation of spiritual needs in patients with cancer
Allison Kestenbaum, Kelly A McEniry, Sarah Friedman, et al.
Journal of Analytical Toxicology
|
March 25, 2014
Naltrexone metabolism and concomitant drug concentrations in chronic pain patients
Janet C Liu, Joseph D Ma, Candis M Morello, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 84) with videos related to
Sort By:
Page
of 9
Clinical Pharmacokinetics
|
May 7, 2021
Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
Shirley M Tsunoda, Christopher Gonzales, Alan K Jarmusch, et al.
Journal of Analytical Toxicology
|
May 1, 2014
Variability in metabolism of imipramine and desipramine using urinary excretion data
Kelley Ramey, Joseph D Ma, Brookie M Best, et al.
Journal of Pain & Palliative Care Pharmacotherapy
|
January 15, 2014
A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients
Joseph D Ma, John M Horton, Michael Hwang, et al.
Journal of Pain & Palliative Care Pharmacotherapy
|
September 12, 2018
Opioid and Benzodiazepine Relative Use in Breast Cancer Patients Before, During, and After Curative Chemotherapy
Warren H Yau, Eric J Roeland, Carolyn Revta, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2006
Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults
Joseph D Ma, Anne N Nafziger, Stephen A Villano, et al.
Journal of Palliative Medicine
|
January 22, 2015
Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants
Andrew R Bruggeman, Sean F Heavey, Joseph D Ma, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
May 1, 2012
Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation
Anh N Nguyen, Justin T Hoffman, Shirley M Tsunoda, et al.
Journal of Opioid Management
|
June 20, 2014
Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine
Jennifer M Cao, Joseph D Ma, Candis M Morello, et al.
Journal of Health Care Chaplaincy
|
December 6, 2021
Spiritual AIM: assessment and documentation of spiritual needs in patients with cancer
Allison Kestenbaum, Kelly A McEniry, Sarah Friedman, et al.
Journal of Analytical Toxicology
|
March 25, 2014
Naltrexone metabolism and concomitant drug concentrations in chronic pain patients
Janet C Liu, Joseph D Ma, Candis M Morello, et al.
Page
of 9